Ophthalmic drug manufacturers are leveraging the growing rate of FDA approvals for novel drug offerings to introduce new products and revenue streams in the market.

ROCKVILLE, MD / ACCESSWIRE / August 13, 2020 / The global ophthalmic drugs market is anticipated to show a moderate growth rate of 4.2% CAGR between the forecasting years from 2020 to 2025. The coronavirus pandemic is likely to have a detrimental impact on the ophthalmic drugs market. Government guidelines postponing elective ophthalmic procedures and consultations are hurting demand for ophthalmic drugs. In addition, fears over covid-19 transmission through ocular secretions is also hampering short term prospects.

'Growing use of novel therapeutics in the field of ophthalmology, coupled with higher numbers of eye ailments, are major drivers for the ophthalmic drugs industry. Further, faster approvals for new offerings and growing patient awareness treatment options will contribute to market developments,' says the FACT.MR analyst.

Request a sample of the report to gain more market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4799

Ophthalmic Drugs Market- Key Takeaways

• OTC drug variants are witnessing strong growth owing to the expiration of patents, and popularity of generic options.
• Ophthalmic drugs for retinal disorders are gaining ground, supported by industry collaborations and associated academic research.
• North America holds a major share of the ophthalmic drugs market, owing to favorable government policies and faster access to new technologies for eyecare infrastructure.

Ophthalmic Drugs Market- Driving Factors

• Rising incidences of eye conditions such as diabetic retinopathy, macular degeneration, and presbyopia contribute to demand for ophthalmic drugs.
• Rapid tech advancements in drug delivery systems account greater adoption of ophthalmic drug offerings.

Ophthalmic Drugs Market- Major Restraints

• Long timelines for regulatory approvals in many parts of the world remains a key challenge for manufacturers.
• Substantial risk of side effects from the administration of ophthalmic drugs holds back market growth.

COVID-19 Impact on Ophthalmic Drugs Market

The coronavirus pandemic is having a negative impact on the ophthalmic drugs market owing to suspension of non-critical operations in the ophthalmic sector of the healthcare industry. In addition, the industry is facing challenges in supply chains, owing to disruptions of raw material production. Concerns over ocular transmission of the virus also hurts short term prospects. However, the market is likely to witness strong recovery post pandemic, driven by high numbers of eye disorder incidences and resurgence of ophthalmic treatment services.

Explore the global Ophthalmic Drugs market with 90 figures, 55 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4799/opthalmic-drugs-market

Competitive Landscape

Santen Pharmaceutical Co., Novartis AG, Allergan, and Regeneron Pharmaceuticals Inc. are some of the leading ophthalmic drug manufacturers in the global market.

Ophthalmic drugs market players displaying greater bias towards the development and launch of new drug formulations to widen their portfolio of solutions for ocular ailments.

For instance, Eyevance has announced the FDA approval of Zerviate, a cetirizine ophthalmic solution aimed towards treating allergic conjunctivitis. Horizon Therapeutics has announced the approval of Teprotumumab for thyroid eye disease in adults. Further, Allergan has also announced the approval of Artemis, a new biodegradable glaucoma implant drug.

About the Report

This study offers readers a comprehensive market forecast of the ophthalmic drugs market. Global, regional and country-level analysis of the top industry trends impacting the ophthalmic drugs market is covered in this FACT.MR study. The report offers insights on the ophthalmic drugs market on the basis of disease indication (dry eye, glaucoma, infection, retinal disorders, allergy, uveitis, and others), therapeutic class (anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF drugs, and others) product type (prescription drugs and OTC drugs) and distribution channel (hospital pharmacies, online pharmacies, and independent pharmacies), across five regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Explore FACT.MR's Comprehensive Coverage of Healthcare Landscape

OTC Vitamins & Dietary Supplements Market- Get the latest insights on the global OTC vitamins & dietary supplements market through FACT.MR's report covering analysis for projection period (2017-2022).

OTC Cough, Cold & Allergy Medicine Market- FACT.MR's study on the global OTC cough, cold & allergy medicine market covers trends, tech innovations, players, and strategies for 2017-2022.

OTC Analgesics Market- Obtain analysis on the global OTC analgesics market through FACT.MR's latest report covering competitive analysis, key regions, along with segmental analysis for 2017-2022.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1567/global-opthalmic-drugs-market

SOURCE: Fact.MR